Author:
You Xiaohua,Guo Zhi-Fu,Cheng Fang,Yi Bing,Yang Fan,Liu Xinzhu,Zhu Ni,Zhao Xianxian,Yan Guijun,Ma Xin-Liang,Sun Jianxin
Funder
HHS | NIH | National Institute of General Medical Sciences (NIGMS)
American Heart Association (AHA)
National Natural Science Foundation of China (NSFC)
HHS | NIH | National Heart, Lung, and Blood Institute
Subject
Cell Biology,Molecular Biology,Biochemistry
Reference44 articles.
1. “Relaxin” the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease;Samuel;Pharmacol. Ther,2006
2. Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises;Nistri;Cardiovasc. Hematol. Agents Med. Chem,2007
3. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease;Samuel;Hypertension,2014
4. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial;Teerlink;Lancet,2013
5. Relaxin: new peptides, receptors and novel actions;Bathgate;Trends Endocrinol. Metab,2003
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献